Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Flack

Showing results (231-240 of 263) with videos related to

Pageof 27
Sort By:
Hypertension (Dallas, Tex. : 1979)|January 22, 2025
Aprocitentan for Blood Pressure Reduction in Black PatientsJohn M Flack, Markus P Schlaich, Michael A Weber, et al.
Heart Disease (Hagerstown, Md.)|April 27, 2002
Coronary heart disease in African AmericansL T Clark, K C Ferdinand, J M Flack, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|November 1, 2016
Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost-effectiveness AnalysisMichael J Twiner, Alexander L Marinica, Kenneth Kuper, et al.
American Journal of Hypertension|August 25, 2022
Does Vitamin D Provide Added Benefit to Antihypertensive Therapy in Reducing Left Ventricular Hypertrophy Determined by Cardiac Magnetic Resonance?Phillip D Levy, Michael J Twiner, Aaron M Brody, et al.
Ethnicity & Disease|November 25, 2003
For the patient. What is the Metabolic Syndrome and why is it important?W Dallas Hall, Luther T Clark, Nanette K Wenger, et al.
Ethnicity & Disease|November 25, 2003
The Metabolic Syndrome in African Americans: a reviewW Dallas Hall, Luther T Clark, Nanette K Wenger, et al.
Lancet (London, England)|March 7, 2026
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trialMichel Azizi, Jenifer M Brown, Jamie P Dwyer, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|August 24, 2025
Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24John M Flack, Michel Azizi, Jenifer M Brown, et al.
Chemsuschem|August 29, 2012
The synthesis and the chemical and physical properties of non-aqueous silylamine solvents for carbon dioxide captureAmy L Rohan, Jackson R Switzer, Kyle M Flack, et al.
Disease Management : DM|February 10, 2006
The metabolic syndrome: recognition and managementW Dallas Hall, Laurence O Watkins, Jackson T Wright, et al.
Pageof 27

Showing results (231-240 of 263) with videos related to

Sort By:
Pageof 27
Hypertension (Dallas, Tex. : 1979)|January 22, 2025
Aprocitentan for Blood Pressure Reduction in Black PatientsJohn M Flack, Markus P Schlaich, Michael A Weber, et al.
Heart Disease (Hagerstown, Md.)|April 27, 2002
Coronary heart disease in African AmericansL T Clark, K C Ferdinand, J M Flack, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|November 1, 2016
Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost-effectiveness AnalysisMichael J Twiner, Alexander L Marinica, Kenneth Kuper, et al.
American Journal of Hypertension|August 25, 2022
Does Vitamin D Provide Added Benefit to Antihypertensive Therapy in Reducing Left Ventricular Hypertrophy Determined by Cardiac Magnetic Resonance?Phillip D Levy, Michael J Twiner, Aaron M Brody, et al.
Ethnicity & Disease|November 25, 2003
For the patient. What is the Metabolic Syndrome and why is it important?W Dallas Hall, Luther T Clark, Nanette K Wenger, et al.
Ethnicity & Disease|November 25, 2003
The Metabolic Syndrome in African Americans: a reviewW Dallas Hall, Luther T Clark, Nanette K Wenger, et al.
Lancet (London, England)|March 7, 2026
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trialMichel Azizi, Jenifer M Brown, Jamie P Dwyer, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|August 24, 2025
Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24John M Flack, Michel Azizi, Jenifer M Brown, et al.
Chemsuschem|August 29, 2012
The synthesis and the chemical and physical properties of non-aqueous silylamine solvents for carbon dioxide captureAmy L Rohan, Jackson R Switzer, Kyle M Flack, et al.
Disease Management : DM|February 10, 2006
The metabolic syndrome: recognition and managementW Dallas Hall, Laurence O Watkins, Jackson T Wright, et al.
Pageof 27